UK consumers scaled back on food and alcohol purchases during the festive season, a trend attributed to the increasing popularity of weight loss injections. Despite a 2.5% rise in overall grocery sales to £19.6 billion for the four weeks ending December 27, sales volume dropped by 0.2%, as reported by market researcher NielsenIQ.
Experts in retail point to the surge in individuals using GLP-1 injections, which emulate a crucial hormone that triggers early satiety. The National Health Service (NHS) recommends Mounjaro and Wegovy for weight loss and Ozempic solely for diabetes treatment. Recent statistics from University College London indicate that approximately 1.6 million adults in the UK have utilized these injections in the past year.
Retail analyst Jonathan De Mello highlighted the “Ozempic effect” as a significant trend affecting grocery sales, with a notable decline in volume among consumers using GLP-1 medications. He emphasized the impact on high-calorie products like snacks and alcohol, suggesting that retailers may need to adjust their product offerings to align with the shift towards “less but better” consumption patterns.
Consumer analyst Clive Black noted that the decrease in grocery volume over the Christmas period reflects the influence of GLP drugs on eating habits across the nation. Several major retailers have responded to this trend by introducing smaller meal options. Co-op unveiled a range of “mini meals” catering to individuals with reduced appetites, while Marks & Spencer launched a new “nutrient dense” selection, and Iceland expanded its frozen meal range with 38 additional options.
The impact of weight loss injections on consumer behavior was also acknowledged by Greggs’ CEO, who observed changes in customer preferences towards smaller portions and healthier choices. Tesco’s chief executive and Sainsbury’s CEO expressed vigilance in monitoring consumer trends, particularly in response to the growing usage of weight loss medication.